Retrograde Intrarenal Surgery versus Percutaneous Nephrolithotomy for Treatment of Renal Stones >2 cm: A Meta-Analysis

医学 经皮肾镜取石术 置信区间 荟萃分析 科克伦图书馆 相对风险 随机对照试验 外科 泌尿科 内科学 经皮
作者
Changjian Zheng,Bo Xiong,Hongzhi Wang,Jun Luo,Chenggou Zhang,Wei Wei,Yarong Wang
出处
期刊:Urologia Internationalis [S. Karger AG]
卷期号:93 (4): 417-424 被引量:52
标识
DOI:10.1159/000363509
摘要

<b><i>Objective:</i></b> To systematically review the efficacy and safety of retrograde intrarenal surgery (RIRS) versus percutaneous nephrolithotomy (PCNL) for the treatment of renal calculi >2 cm. <b><i>Methods:</i></b> We searched PubMed, Cochrane Library, Embase and the Chinese Biomedical Literature Database about RIRS and PCNL for the treatment of renal stones. The retrieval time ended in December 2013. All clinical trials were retrieved and their included references investigated. Two reviewers independently assessed the quality of all included studies, and the eligible studies were included and analyzed using the RevMan 5.2 software. <b><i>Results:</i></b> Two randomized controlled trials and six clinical controlled trials were included, involving a total of 590 patients. Our meta-analysis showed that there were not significant differences in stone-free rate (relative risk [RR] = 0.95, 95% confidence interval (CI) 0.88-1.02, p = 0.11) and fever (RR = 0.95, 95% CI 0.54-1.67, p = 0.85) between RIRS and PCNL. We found that hospital stay (weighted mean difference [WMD] = -2.10, 95% CI -3.08 to -1.11, p < 0.10) and bleeding (RR = 0.20, 95% CI 0.06-0.68, p = 0.01) were lower and operation time was longer (WMD = 19.11, 95% CI 7.83-30.39, p < 0.10) for RIRS. <b><i>Conclusion:</i></b> RIRS is a safe and effective procedure. It can successfully treat patients with stones >2 cm with a high stone-free rate and significantly reduce hospital stay without increasing complications. RIRS can be used as an alternative treatment to PCNL in selected cases with larger renal stones. However, further randomized trials are needed to confirm these findings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XXXXH发布了新的文献求助10
刚刚
xiaozhangzi完成签到,获得积分10
1秒前
chigga发布了新的文献求助10
1秒前
隐形曼青应助beautiful540采纳,获得20
2秒前
R喻andom发布了新的文献求助10
4秒前
4秒前
李健应助zizi采纳,获得10
5秒前
5秒前
6秒前
劲秉应助阳光照采纳,获得10
9秒前
Gyrfalcon完成签到 ,获得积分10
9秒前
一棵树发布了新的文献求助10
9秒前
不配.应助科研通管家采纳,获得10
9秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
不配.应助科研通管家采纳,获得10
10秒前
不配.应助科研通管家采纳,获得10
10秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
甜滋滋发布了新的文献求助10
10秒前
青阳完成签到,获得积分10
11秒前
多多发SCI完成签到,获得积分10
13秒前
科研通AI2S应助拼搏的秋玲采纳,获得10
14秒前
zpzz完成签到 ,获得积分10
15秒前
我一进来就看到常威在打来福完成签到,获得积分10
16秒前
小二郎应助jhnl采纳,获得10
17秒前
科研通AI2S应助111采纳,获得10
20秒前
neilphilosci完成签到 ,获得积分10
20秒前
EddyLalala给kejiwangzi的求助进行了留言
21秒前
24秒前
南宫秃完成签到,获得积分0
25秒前
27秒前
充电宝应助投石问路采纳,获得10
27秒前
27秒前
aiiLuX完成签到 ,获得积分10
28秒前
29秒前
深情依霜发布了新的文献求助10
29秒前
万里发布了新的文献求助10
31秒前
32秒前
111发布了新的文献求助10
32秒前
jhnl发布了新的文献求助10
32秒前
孙兆杰完成签到,获得积分10
33秒前
高分求助中
Medicina di laboratorio. Logica e patologia clinica 600
Sarcolestes leedsi Lydekker, an ankylosaurian dinosaur from the Middle Jurassic of England 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
Language injustice and social equity in EMI policies in China 500
mTOR signalling in RPGR-associated Retinitis Pigmentosa 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Geochemistry, 2nd Edition 地球化学经典教科书第二版 401
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3214629
求助须知:如何正确求助?哪些是违规求助? 2863251
关于积分的说明 8137704
捐赠科研通 2529429
什么是DOI,文献DOI怎么找? 1363682
科研通“疑难数据库(出版商)”最低求助积分说明 643903
邀请新用户注册赠送积分活动 616437